Tuesday, 25 November 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 25 November 2025
News

Billion dollar 'No' for Lilly drug

Posted 25 November 2025 PM

MSAC has dealt blow to Eli Lilly in its bid to provide its Alzheimer's drug Kisunla to the Australian population, failing to support Government funding for necessary tests which have an estimated price tag of a billion dollars over six years.

In the latest challenge to funded access to the new treatment, MSAC said it did not support public funding on the MBS for two tests that can determine eligibility for treatment with Kisunla by checking for amyloid-beta proteins in the brain.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (14)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.